| |
|
|
|
The Center for Professional Advancement, An Online Training Format
February 12, 2008
Who Should Attend
This course is an excellent foundation for planning and implementing program development and change, in both the small-molecule and biologic drug industries. The course extends from the present through 2020, considered by industry observers as the vital reshaping period for Pharma. It is recommended for: - Development and production program managers
- New-product oversight leaders
- Quality Risk Managers
- Department and group managers
- New senior-staff employees
- Investors and business developers
Description
This intensive 90-minute course focuses on these key industry drivers: change in the global market mix, product pipelines, generics, product life cycle, development & manufacturing efficiency, emerging biologics, and profits. Following benchmark review, the course provides footprints for turnaround strategies.
Module 1:
The evolving global drug business Industry benchmarks How did we get here? Where we are going
Module 2:
Pipeline and product issues Lifting the regulatory veil The new ethical, biologic and generic drug mix Critical path and Quality Risk Management
Module 3:
Risk & reward from development through manufacturing Niche focus for drug products Outsourcing and plant capacity Turnaround strategies
|
|
|
|
|
|
|
|
Organized by:
|
|
The Center for Professional Advancement |
|
|
Invited Speakers:
|
|
John E. Carroll, C.Ph.C. is Managing Partner, Cadrai Technology Group and President, Carroll Ventures, Inc. The Cadrai Technology Group develops and presents focused training programs for issues germane to the current needs of the analytical instrument industry, especially regarding Pharmaceutical applications. As Managing Partner for Cadrai LLC., Mr. Carroll modified and introduced ion mobility spectrometers for cleaning verification, an automated fiber optic/UV sensed dissolution apparatus for rapid pharmaceutical product screening and numerous Near-Infrared spectrometric systems for dedicated pharmaceutical applications. All products used proprietary technology of the principal clients.
As Pharmaceutical Business Unit Manager, for Perstorp Analytical Instruments (now Foss), Mr. Carroll built a global, sustainable business that saw over 8,000 NIR test instruments placed within the pharmaceutical manufacturing industry.
Mr. Carroll has a B.A.S in Engineering Technology/Chemistry, a M.B.A. (c) in International Marketing, fifty publications and is the author of “The NIR Desk Reference”, (Carroll, He and Landa) and “The Handbook of FTIR”, (Carroll). He is also the editor of “IR-MS: High sensitivity and selectivity for organic analysis”. (Mattson and Carroll).
|
|
|
|
|
|
|
|
Deadline for Abstracts:
|
|
n/a
|
|
|
|
|
|
|
|
Registration:
|
|
Please click here for registration information.
|
|
|
E-mail:
|
|
info@cfpa.com
|
|
|
|
|
|
|
|
|